646 reports of this reaction
1.4% of all BIMATOPROST reports
#16 most reported adverse reaction
EYE SWELLING is the #16 most commonly reported adverse reaction for BIMATOPROST, manufactured by Allergan, Inc.. There are 646 FDA adverse event reports linking BIMATOPROST to EYE SWELLING. This represents approximately 1.4% of all 44,865 adverse event reports for this drug.
Patients taking BIMATOPROST who experience eye swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
EYE SWELLING is a less commonly reported adverse event for BIMATOPROST, but still significant enough to appear in the safety profile.
In addition to eye swelling, the following adverse reactions have been reported for BIMATOPROST:
The following drugs have also been linked to eye swelling in FDA adverse event reports:
EYE SWELLING has been reported as an adverse event in 646 FDA reports for BIMATOPROST. This does not prove causation, but indicates an association observed in post-market surveillance data.
EYE SWELLING accounts for approximately 1.4% of all adverse event reports for BIMATOPROST, making it a notable side effect.
If you experience eye swelling while taking BIMATOPROST, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.